Table 1.3
Summary of numerous in vivo and in vitro studies indicating health effects of soybean and its bioactive components
Experimental model
The form of soya bean
Dose and route of
administration
Investigation
Major
finding/s
Reference
Human
(DM patients)
Roasted soya bean
powder
69 g/d for 4 weeks
Assay of glycemic control and
lipid metabolism parameters
Hypolipidemic,
hypoglycemic, and
antioxidant activity
Chang et al.
(2008)
Sprague-Dawley
rats
Isolated soy protein
(ISP) and genistein
STZ-genistein, 600 mg/kg
diet, and STZ-ISP, 200 g/kg
diet for 3 weeks
Assay of blood glucose, lipid
metabolism parameters, and
antioxidant enzymes
Hypolipidemic,
hypoglycemic, and
antioxidant activity
Lee (2006)
Human
(DM patients)
Soy-based dietary
supplement
Abalon (50 g soy protein,
165 mg isoflavones, and 20 g
cotyledon
fiber)/day for
6 weeks
Assay of blood glucose, lipid
metabolism parameters
Hypolipidemic
Hermansen
et al. (2001)
Human (hypercholesterolemic patients)
Soy-based dietary
supplement
Abalon (30 g soy protein, 9 g
cotyledon
fiber, and 100 mg
isoflavones)/day for 24 weeks
Assay of LDL cholesterol and
other cardiovascular risk factors (including endothelial
function)
Hypolipidemic
Hermansen
et al. (2005)
Human (postmenopausal diabetic
women)
Phytoestrogens
Phytoestrogens (soy protein
30 g/d, isoflavones 132 mg/d)/
day for 12 weeks
Assay of glycemic control and
cardiovascular risk markers
Hypolipidemic,
hypoglycemic, and
cardioprotective
effect
Jayagopal
et al. (2002)
Human
(diabetic women)
Soy isoflavones
435 mg/d for 2 months
Assay of blood glucose, lipid
metabolism parameters
Hypolipidemic and
reduced risk of
diabetes
Chi et al.
(2016)
Human
(obese diabetic
patients)
Soy-based meal replacement (MR) plan
12 months
Assay of weight loss and metabolic profile
Weight reduction
and hypoglycemic
effect
Li et al.
(2005)
Human (postmenopausal women)
Soy isoflavones
40–80 mg/d for 1 year
Assay of blood glucose, lipid
metabolism parameters
Hypoglycemic
Ho et al.
(2007a, b)
12
R. Modgil et al.
Summary of numerous in vivo and in vitro studies indicating health effects of soybean and its bioactive components
Experimental model
The form of soya bean
Dose and route of
administration
Investigation
Major
finding/s
Reference
Human
(DM patients)
Roasted soya bean
powder
69 g/d for 4 weeks
Assay of glycemic control and
lipid metabolism parameters
Hypolipidemic,
hypoglycemic, and
antioxidant activity
Chang et al.
(2008)
Sprague-Dawley
rats
Isolated soy protein
(ISP) and genistein
STZ-genistein, 600 mg/kg
diet, and STZ-ISP, 200 g/kg
diet for 3 weeks
Assay of blood glucose, lipid
metabolism parameters, and
antioxidant enzymes
Hypolipidemic,
hypoglycemic, and
antioxidant activity
Lee (2006)
Human
(DM patients)
Soy-based dietary
supplement
Abalon (50 g soy protein,
165 mg isoflavones, and 20 g
cotyledon
fiber)/day for
6 weeks
Assay of blood glucose, lipid
metabolism parameters
Hypolipidemic
Hermansen
et al. (2001)
Human (hypercholesterolemic patients)
Soy-based dietary
supplement
Abalon (30 g soy protein, 9 g
cotyledon
fiber, and 100 mg
isoflavones)/day for 24 weeks
Assay of LDL cholesterol and
other cardiovascular risk factors (including endothelial
function)
Hypolipidemic
Hermansen
et al. (2005)
Human (postmenopausal diabetic
women)
Phytoestrogens
Phytoestrogens (soy protein
30 g/d, isoflavones 132 mg/d)/
day for 12 weeks
Assay of glycemic control and
cardiovascular risk markers
Hypolipidemic,
hypoglycemic, and
cardioprotective
effect
Jayagopal
et al. (2002)
Human
(diabetic women)
Soy isoflavones
435 mg/d for 2 months
Assay of blood glucose, lipid
metabolism parameters
Hypolipidemic and
reduced risk of
diabetes
Chi et al.
(2016)
Human
(obese diabetic
patients)
Soy-based meal replacement (MR) plan
12 months
Assay of weight loss and metabolic profile
Weight reduction
and hypoglycemic
effect
Li et al.
(2005)
Human (postmenopausal women)
Soy isoflavones
40–80 mg/d for 1 year
Assay of blood glucose, lipid
metabolism parameters
Hypoglycemic
Ho et al.
(2007a, b)
12
R. Modgil et al.